Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure (DotArv)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01433601 |
Recruitment Status
: Unknown
Verified September 2011 by Mattias Larsson, Karolinska Institutet.
Recruitment status was: Active, not recruiting
First Posted
: September 14, 2011
Last Update Posted
: September 14, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Human Immunodeficiency Virus (HIV) | Behavioral: Enhanced Treatment Support (ETS) | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 640 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | A Randomised Controlled Trial to Assess Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure |
Study Start Date : | August 2007 |
Estimated Primary Completion Date : | November 2011 |
Estimated Study Completion Date : | November 2011 |

Arm | Intervention/treatment |
---|---|
No Intervention: Self Supervised Treatment (SST)
Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
|
|
Experimental: Enhanced Treatment Support (ETS)
Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
|
Behavioral: Enhanced Treatment Support (ETS)
An "internal supporter" - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. An"external supporter" - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup.
Other Names:
|
- Virological treatment failure [ Time Frame: 24 months ]HIV viral load of 1 fg reverse transcriptase activity/ml, corresponding to 200 copies/ml, at 1 year and 2 years after starting treatment.
- Immunological treatment failure [ Time Frame: 24 months ]
Immunological treatment failure
- CD4 count returns to or falls below pre-therapy baseline level or
- 50% decline from the on-treatment peak value since the initiation of ART (if known); or
- CD4 count < 100 cells/mm3 after a year without any increase.
- Clinical treatment failure [ Time Frame: 24 months ]Occurrence or recurrence of stage 4 diseases or conditions after at least 6 months of therapy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 59 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- WHO stage IV of HIV disease, regardless of the CD4 count
- WHO stage III of HIV disease with a CD4 count < 350/mm3
- WHO stages I or II with a CD4 count < 200/mm3
Exclusion Criteria:
- Pregnancy
- Ongoing severe opportunistic infections
- Institutionalized patients.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01433601
Vietnam | |
Hanoi Medical University | |
Hanoi, Vietnam, 01 |
Principal Investigator: | Mattias Larssson, Md PhD | Karolinska Institutet |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Mattias Larsson, MD PhD, Karolinska Institutet |
ClinicalTrials.gov Identifier: | NCT01433601 History of Changes |
Other Study ID Numbers: |
DotArv_Vietnam |
First Posted: | September 14, 2011 Key Record Dates |
Last Update Posted: | September 14, 2011 |
Last Verified: | September 2011 |
Keywords provided by Mattias Larsson, Karolinska Institutet:
Adherence Peer support Treatment failure |
Additional relevant MeSH terms:
Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections |
RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases |